Clover advances with Dynavax on COVID-19 vaccine and drops GSK partnership
China’s Clover Biopharmaceuticals is to begin a global Phase II/III trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with US firm Dynavax Technologies' (Nasdaq: DVAX) CpG 1018 plus alum.
The study will start in the first half of this year, with an interim analysis for vaccine efficacy potentially in the middle of 2021.
"Given the encouraging results of our adjuvanted s-trimer COVID-19 vaccine candidate to-date, we are enthusiastic about progressing to a global Phase II/III efficacy study utilizing Dynavax’s advanced adjuvant CpG 1018 plus alum"The Coalition for Epidemic Preparedness Innovations (CEPI) will continue to support the development of Clover’s COVID-19 vaccine candidate and will fund the development, including the Phase II/III trial, through licensure.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze